Our goal: to give patients their best chance at survival
by disrupting the chaos of aggressive cancers
Innovative developments in mitochondrial research
for rare and aggressive cancers
Recent Presentation
ASCO ANNUAL MEETING 2024
MITOPE Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor
Presenter: Sean Dulloo, Mesothelioma Research Programme, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
ASCO PUBLICATIONS Abstract
Helpful Materials for Healthcare Professionals
Download posters, brochures, quick links to videos and find key contact information.
Resources
Sarcomatoid tumors are highly resistant
to anti-cancer therapies, and many patients run out of available treatment options. Our findings might have unveiled a druggable ‘Achilles Heel’ against this terrible disease.”
– Dean Fennell, MRCP, FCRP
Covalent inactivation of PRX3 by RSO-021
represents a viable anticancer approach by targeting a universal tumor vulnerability of oxidative stress. The results we present at the AACR Annual Meeting will highlight fundamental tumor cell features that are exploitable by this novel treatment.”
– Brian Cunniff, Chief Science Officer
While there have been recent advances
in immunotherapy and targeted therapy for patients with lung cancer, this cancer remains responsible for the largest burden of cancer mortality in both men and women worldwide. Dedicated studies of novel therapies for this disease and its clinical complications such as pleural effusions, should be supported- and meets an unmet clinical need”
– Jarushka Naidoo, Professor of Medical Oncology; Consultant Medical Oncologist at Beaumont RCSI Cancer Centre Dublin
Pleural space access is crucial for intrapleural trials.
Based on previous experience, it seems likely that access issues will be minimised using first-line designs. Given the absence of a proven standard of care in pleura-only PM, such trial designs would, in our view, be scientifically justified and ethical, assuming careful radiological staging to identify disease more suitable for licensed systemic therapies.”
– Kevin Blyth, Medical Consultant, Glasgow University
